Dyne Therapeutics (NASDAQ:DYN) Earns Outperform Rating from Analysts at Robert W. Baird

Robert W. Baird began coverage on shares of Dyne Therapeutics (NASDAQ:DYN) in a research report issued to clients and investors on Friday,Briefing.com Automated Import reports. The brokerage set an “outperform” rating and a $46.00 price target on the stock. Robert W. Baird’s price objective indicates a potential upside of 79.62% from the stock’s previous close.

DYN has been the topic of several other reports. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of Dyne Therapeutics in a report on Wednesday, November 13th. JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and cut their price target for the company from $43.00 to $35.00 in a report on Thursday, October 24th. Royal Bank of Canada began coverage on shares of Dyne Therapeutics in a research report on Tuesday, November 26th. They issued an “outperform” rating and a $45.00 price objective for the company. Chardan Capital reissued a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research report on Wednesday, November 13th. Finally, StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $50.42.

Dyne Therapeutics Stock Down 6.8 %

Dyne Therapeutics stock opened at $25.61 on Friday. The company’s 50-day moving average price is $30.53 and its 200-day moving average price is $35.24. Dyne Therapeutics has a twelve month low of $10.80 and a twelve month high of $47.45. The company has a market cap of $2.61 billion, a PE ratio of -7.19 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, sell-side analysts expect that Dyne Therapeutics will post -3.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,390 shares of the company’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total transaction of $48,024.50. Following the transaction, the senior vice president now owns 98,568 shares in the company, valued at approximately $3,405,524.40. This represents a 1.39 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Susanna Gatti High sold 8,976 shares of the stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total transaction of $308,864.16. Following the completion of the sale, the chief operating officer now owns 131,636 shares in the company, valued at $4,529,594.76. The trade was a 6.38 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 180,046 shares of company stock worth $6,300,265 in the last 90 days. 20.77% of the stock is owned by corporate insiders.

Institutional Trading of Dyne Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in Dyne Therapeutics by 69.7% during the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after purchasing an additional 3,707,734 shares in the last quarter. RTW Investments LP lifted its holdings in Dyne Therapeutics by 6.8% during the third quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock valued at $244,926,000 after purchasing an additional 431,503 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Dyne Therapeutics by 47.3% during the third quarter. Janus Henderson Group PLC now owns 6,813,163 shares of the company’s stock valued at $244,755,000 after purchasing an additional 2,189,339 shares in the last quarter. RA Capital Management L.P. lifted its holdings in Dyne Therapeutics by 5.5% during the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock valued at $229,211,000 after purchasing an additional 331,940 shares in the last quarter. Finally, State Street Corp lifted its holdings in Dyne Therapeutics by 13.8% during the third quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after purchasing an additional 440,890 shares in the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.